On January 12, 2012, the Center for Cell Engineering at Memorial Sloan Kettering Cancer Center hosted its fifth annual retreat. In a symposium focusing on engineering hematopoiesis, invited investigators presented recent advances in understanding and controlling hematopoietic stem cell development, and discussed how these discoveries could offer new therapeutic opportunities.

Opening remarks by Michel Sadelain, Director of the Center for Cell Engineering

Gordon Keller (McEwen Centre for Regenerative Medicine, Ontario Cancer Institute)

Igor Sluvkin (University of Wisconsin)

Christopher Kloss, a graduate student in Michel Sadelain's laboratory, asks a follow-up question after Dr. Slukvin's presentation.

Mick Bhatia (McMaster Stem Cell and Cancer Research Institute, McMaster University)

Shahin Rafii (Weill Cornell Medical College)

Daylon James (Weill Cornell Medical College)

Directed differentiation of human pluripotent stem cells
Gordon Keller, PhD
McEwen Centre for Regenerative Medicine
Ontario Cancer Institute, Canada

Mesodermal specification and hematopoietic commitment of human pluripotent stem cells
Igor Slukvin, MD, PhD
Department of Pathology and Laboratory Medicine
University of Wisconsin

Programming human hematopoiesis
Mick Bhatia, PhD
McMaster Stem Cell and Cancer Research Institute
McMaster University, Canada

Vascular niche-derived angiocrine factors in organ regeneration
Shahin Rafii, MD
Department of Genetic Medicine
Weill Cornell Medical College